Foresite Capital Management IV
Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Kinnate Biopharma, KROS, RLAY, ALXO, NRIX, and represent 79.77% of Foresite Capital Management IV's stock portfolio.
- Added to shares of these 4 stocks: Kinnate Biopharma (+$385M), Olema Pharmaceuticals (+$39M), KURA (+$16M), ACRS (+$5.2M).
- Started 2 new stock positions in Olema Pharmaceuticals, Kinnate Biopharma.
- Reduced shares in these 6 stocks: Myokardia (-$17M), ABUS (-$10M), VYGR (-$5.5M), CYTK, PANA.U, NRIX.
- Sold out of its positions in ABUS, Myokardia, PANA.U, VYGR.
- Foresite Capital Management IV was a net buyer of stock by $406M.
- Foresite Capital Management IV has $921M in assets under management (AUM), dropping by 107.60%.
Tip: Access up to 7 years of quarterly data
Positions held by Foresite Capital Management IV, LLC consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Foresite Capital Management IV
Companies in the Foresite Capital Management IV portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kinnate Biopharma | 41.8 | $385M | NEW | 9.7M | 39.78 | |
| Keros Therapeutics (KROS) | 10.8 | $100M | 1.4M | 70.54 | ||
| Relay Therapeutics (RLAY) | 9.7 | $89M | 2.1M | 41.56 | ||
| Alx Oncology Hldgs (ALXO) | 9.1 | $84M | 974k | 86.20 | ||
| Nurix Therapeutics (NRIX) | 8.4 | $77M | 2.3M | 32.88 | ||
| Kura Oncology (KURA) | 6.4 | $59M | +38% | 1.8M | 32.66 | |
| Olema Pharmaceuticals | 4.3 | $39M | NEW | 818k | 48.08 | |
| Cytokinetics (CYTK) | 3.2 | $30M | -14% | 1.4M | 20.78 | |
| Generation Bio (GBIO) | 2.6 | $24M | 858k | 28.35 | ||
| Vaxcyte (PCVX) | 1.3 | $12M | 466k | 26.57 | ||
| Cymabay Therapeutics (CBAY) | 1.1 | $10M | 1.8M | 5.74 | ||
| Aclaris Therapeutics (ACRS) | 0.7 | $6.2M | +556% | 951k | 6.47 | |
| Therapeutics Acquisition Corp Com Cl A (RACA) | 0.5 | $4.9M | 350k | 13.92 |
Past Filings by Foresite Capital Management IV
SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017
- Foresite Capital Management IV 2020 Q4 filed Feb. 16, 2021
- Foresite Capital Management IV 2020 Q3 filed Nov. 13, 2020
- Foresite Capital Management IV 2020 Q2 filed Aug. 13, 2020
- Foresite Capital Management IV 2020 Q1 restated filed May 28, 2020
- Foresite Capital Management IV 2020 Q1 filed May 14, 2020
- Foresite Capital Management IV 2019 Q4 filed Feb. 14, 2020
- Foresite Capital Management IV 2019 Q3 filed Nov. 13, 2019
- Foresite Capital Management IV 2019 Q2 filed Aug. 13, 2019
- Foresite Capital Management IV 2019 Q1 filed May 14, 2019
- Foresite Capital Management IV 2018 Q4 filed Feb. 13, 2019
- Foresite Capital Management IV 2018 Q3 filed Nov. 13, 2018
- Foresite Capital Management IV 2018 Q2 filed Aug. 14, 2018
- Foresite Capital Management IV 2018 Q1 filed May 15, 2018
- Foresite Capital Management IV 2017 Q4 filed Feb. 13, 2018